Snap Inc. (SNAP) is facing an investigation by the US Department of Justice and the Securities and Exchange Commission over disclosures related to its IPO, as per a report by Reuters.
The agencies subpoenaed the company for details about its IPO, which took place last March, following a lawsuit by shareholders who claim Snap provided misleading information about its rivalry with Facebook’s (FB) subsidiary Instagram.
Snap was also accused of not disclosing another lawsuit that cropped up prior to the IPO in which an ex-employee claimed the company misreported user metrics. Snap termed the lawsuit meritless and said it was cooperating with the investigation.
Snap attained a market cap of nearly $30 billion after its stock soared over 40% shortly after its debut. However, the company’s market value has dropped drastically since then and now stands at just over $8.6 billion.
The investors behind the lawsuit have alleged that Snap downplayed its competition with Instagram, whose Stories feature, despite being a copy of Snapchat Stories, has more users than Snap. Facebook has reportedly cloned several of Snapchat’s features for its own service Instagram, and this has impacted Snap’s user growth significantly.
In its most recent quarter, Snap’s daily active users (DAU) grew 5% versus the year-ago period but fell 1% sequentially to 186 million. Snap’s DAU has dropped sequentially over the first three quarters of this year.
Losing users to Instagram is not the only problem for Snap. The company has seen a slew of top executives leave this year with the most recent one being its VP of Content Nick Bell. Others include its Chief Financial Officer, Chief Strategy Officer as well as the VPs of Product and Sales, respectively. Snap’s flawed redesign effort also took a toll on its user numbers.
Over the past one month, Snap’s shares have dropped over 8%. As of 2:00 pm ET, the stock was down 4.1%.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
